NCT06317870 Pericapsular Nerve Block Versus Intrathecal Morphine for Analgesia After Primary Hip Arthroplasty
| NCT ID | NCT06317870 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire Vaudois |
| Condition | Analgesia |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-09-10 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2024-09-10 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this clinical trial is to compare the analgesic effect of pericapsular nerve block (PENG) with intrathecal morphine in patients scheduled for total hip replacement surgery. The main question to be answered is whether the PENG block is equivalent to intrathecal morphine in reducing postoperative pain. Participants will be randomised into two groups. Patients assigned to the PENG group will receive spinal anaesthesia with local anaesthetic (isobaric bupivacaine) alone and a PENG block. Patients assigned to the intrathecal morphine (ITM) group will receive spinal anaesthesia with a mixture of local anaesthetic (isobaric bupivacaine) and morphine (100 mcg) and a sham PENG block to ensure patient blinding.
Eligibility Criteria
Inclusion Criteria: * Male and female patients * ASA (American Society of Anaesthesiologists) I-III * 18 years of age or older * Patients scheduled for elective primary hip arthroplasty * Able to give written conformed consent autonomously Exclusion Criteria: * Refusal or inability to give consent * Allergy to any of: ropivacaine, paracetamol, ibuprofen, ketorolac, morphine, ondansetron or dexamethasone * Bleeding diathesis * Neurological deficit of the operative side * Existing preoperative opioid use * Renal insufficiency (GFR\<30ml/min according to the Cockroft-Gault formula) * Hepatic insufficiency * Pregnant or lactating women
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06317870 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Analgesia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06317870 currently recruiting?
Yes, NCT06317870 is actively recruiting participants. Contact the research team at eric.albrecht@chuv.ch for enrollment information.
Where is the NCT06317870 trial being conducted?
This trial is being conducted at Lausanne, Switzerland.
Who is sponsoring the NCT06317870 clinical trial?
NCT06317870 is sponsored by Centre Hospitalier Universitaire Vaudois. The trial plans to enroll 80 participants.